The latest update is out from Recursion Pharmaceuticals ( (RXRX) ).

Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair, ...

Recursion Pharmaceuticals has had a rough longer term share price record, yet fresh clinical updates are keeping attention on ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.36 per share a year ago. These ...

Recursion Pharmaceuticals, Inc. Announces Sanofi Options Potential First-In-Class Immunology Development Candidate From Their Collaboration CI Oct. 15 Recursion Prices $200 Million Stock Offering, ...

Recursion Pharmaceuticals RXRX, a TechBio company, is expected to beat expectations when it reports third-quarter 2026 ...

Recursion Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported sales was USD 18.06 million ...

Recursion announced new positive Phase 2 data from the ongoing TUPELO trial of REC-4881, an investigational, oral MEK1/2 inhibitor for familial adenomatous ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Webinar will include earnings updates and REC-4881 data as well as KOL and patient panels, presented live from CGA-IGC on Tuesday, November 3, ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.